Table 5

Characteristics of included trials of Low Level Laser Therapy for pain relief in patients with knee osteoarthritis

First author, publication year

Intervention type, treatment period

No of patients on active therapy (n = 187)

Method quality

Mean baseline pain (mm VAS)

Best mean difference (95% CI) of change over placebo (mm VAS)

Outcome assessment timepoints (weeks, best time point used in bold)


Bulow-94**

25 mW, 830 nm, 2.25 J to 10 points 3 times/week, 9 total sessions

15

2

82.0

8.0 (-10.8 to 26.8)

3, 6

Gøtte-95

12 mW, 904 nm, 12 J in 4 points, 3 times/week 12 total sessions

20

3

69.0

25.0 (9.4 to 40.7)

4

Gur-03

10 mW, 904 nm, 2 or 3 J applied to 2 points, 2–3 times week/10 total sessions

60

4

73.9

25.0 (18.9 to 31.1)

4, 8, 12

Hegedu-06

50 mW, 830 nm, 6 J applied to 8 points, 2 times/week, total 8 sessions

14

3

57.5

25.1 (2.5 to 47.7)

4, 6, 12

Nivbrant-92

4 mW 904 nm, 0.7 J in 3 points, 3 times/week, 6 total sessions

15

4

67

19 (2.4 to 35.6)

2, 6

Stelian-92

2.7 mW and 25 mW 904 + 820 nm, 1.3 J and 11.1 J in two points 10 times/week, 20 total sessions

18

4

72.0

41 (25.4 to 56.6)

2, 10

Tascioglu-05**

50 mW 830 nm, 1.5 or 3 J in 5 points, 5 times/week, 10 total sessions

20

3

66.5

-0.9 (-11.8 to 10)

3

Yurtkuran-06 **

4 mW, 904 nm, 0.48 J in one acupoint (Sp9), 5 times/week, 10 total sessions

25

5

-

-0.7 (-18.6 to 17.2)

2, 12

Best within 4 weeks, all trials††

187

17.7 † (8.1 to 27.3)

Best within 4 weeks, optimal

142

24.2 (17.3 to 31.1)

6–8 weeks

104

15.5 (9.9 to 20.9)

12 weeks

99

12.3 (6.7 to 17.9)

Total

187

3.5*

70.3†

3*


*Mean † Weighted mean †† Random effects model used for calculation ** Non-optimal dose

Bjordal et al. BMC Musculoskeletal Disorders 2007 8:51   doi:10.1186/1471-2474-8-51

Open Data